Quando a ciência é substituída pela política - o caso da ivermectina e o naufrágio da esquerda na pandemia [Parte I de II]
Pode um medicamento ser cancelado por outra razão que não seja científica e, pior, sem qualquer debate independente e aberto ao contraditório?
Em português fluente: jamais um medicamento pode ser validado ou cancelado por razões políticas. Eis um quase consenso, já que praticamente ninguém concorda com cancelamento político de um remédio. Muito menos quando ele trata doenças importantes, praticamente não traz efeitos adversos e já é uma droga com sua segurança confirmada pela prática de décadas, um medicamento reposicionado, velho conhecido da medicina.
Seria um contrassenso cancelar um medicamento assim (ou qualquer outro) por razões ideológicas.
E, no entanto, esse nonsense atravessou a pandemia e segue de pé; o tratamento nos primeiros dias da doença, com medicamentos reposicionados foi, no Brasil, combatido pela esquerda por critérios fundamentalmente ideológicos. E jamais ocorreu o debate público, ouvindo-se o contraditório (este foi censurado, cancelado, vilipendiado, mesmo quando oriundo do campo científico; uma ação orquestrada, “consorciada”, pelo grande capital na Big Mídia).
A esquerda – que se autoproclama defensora dos que vivem do trabalho - jamais aceitou travar o debate científico do medicamento e foi binária e “política” todo o tempo: se Bolsonaro defende somos contra. Um evidente naufrágio da dialética.
Por que? Porque – além da antidialética e da idiotice do binarismo - já se podia observar, no primeiro semestre de 2020, em vários países, inclusive na A.Latina, bem antes das injeções experimentais serem impostas, que a ivermectina funcionava contra o coronavírus, tratando muito bem essa virose respiratória; tanto assim que médicos e alguns hospitais de vários países começaram a usá-la. E outras opções despatenteadas, como a vitamina D e o zinco também surgiram.
E eis que, prontamente, foi deflagrada uma gigantesca campanha pela Big Mídia, Big Pharma e autoridades sanitárias de Estado, a começar pela OMS, contra a ivermectina (também contra a hidroxicloroquina) como se a praga fosse o tratamento e não a doença. E como se não fossem medicamentos que constam da própria lista da OMS.
Também começou, desde o início da pandemia, o cancelamento, a censura sistemática, apareceram os bem lubrificados “checadores de fatos” (pagos pela própria Big Pharma) tudo sempre feito “em nome da ciência”, pelo nosso bem, mas autocraticamente, isto é, censurando o que pode ou não pode ser publicado, mesmo do campo científico; só se divulgava o que a OMS queria. E a esquerda organizada? Sempre detrás da OMS (como se esta agência imperialista, das indústrias de vacinas, fosse neutra...) e invariavelmente operando contra a liberdade de expressão científica.
Reputações médicas e científicas foram acossadas e derrubadas das redes sociais, muitos perseguidos e rotulados, no mínimo, como charlatães (mesmo quando acumulavam títulos científicos de que carecem os jornalistas e ministros de Saúde em geral). Vídeos foram derrubados. A palavra ivermectina foi censurada.
O motivo sempre o mesmo: o dogma, gritado a plenos pulmões pelo stablishment de que era preciso esperar a vacina, de que “só a vacina salva” (quando, no real, esta, se funcionasse, seria apenas prevenção, jamais tratamento) e que “não há evidências” de nenhuma droga contra o coronavírus (só quando for patenteada/cara). Como esse dogma vem sendo repetido! Todos os dias por todos os lados do mainstream. E das publicações da esquerda organizada.
Um dogma altamente lucrativo para a indústria de vacinas, um dogma que, para existir, precisava de que se sabotasse qualquer informação positiva sobre a ivermectina (e a hidroxicloroquina, a vitamina D, o zinco etc), se fazia necessário que todo influencer do sistema ficasse repetindo que “não há evidências”.
Debater, de fato, o sistema nunca aceitou, a esquerda vetou, sempre (“em nome da ciência”, isto é, do conceito pervertido que ela adota de ciência, ao colocar um sinal de igualdade entre ciência e consenso, igualdade que não pode jamais existir já que se o consenso for imposto à ciência, o resultado seria que a real ciência jamais avançaria).
Mas a verdade é que nunca faltaram evidências (ver mini lista de referências ao final desta nota). Sobraram e sobram evidências, as quais, não obstante, jamais apareceram na Globo ou na Big Mídia controlada pelos mesmos megafundos – diga-se de passagem - que controlam a Big Pharma. E que lucram com o dogma.
Esta semana (primeira quinzena de janeiro de 2023) saiu mais um artigo, agora “padrão ouro”, que mostra, contra toda a campanha na direção contrária, que a ivermectina funciona plenamente contra esse coronavírus e outros (além de vírus diferentes); foi divulgado pelo movimento Médicos Pela Vida (A).
Obviamente, e mais uma vez, não vai sair na mídia. E será boicotado pela esquerda.
Caso contrário, começaria a ser derrubada toda a farsa contra a ivermectina para impor as inoculações experimentais; o que alimentaria imediatamente a dúvida óbvia: já que sempre existiu tratamento para essa doença respiratória, por que cargas d água alguém iria querer, livremente, a injeção experimental uma vez gripado?
Mas as autoridades de Estado foram ágeis: de mãos dadas com o judiciário, a mídia amestrada e a esquerda capituladora, defenderam a inoculação compulsória. Esta esquerda deu todo apoio à demissão de quem não se deixasse inocular e, em uma palavra, enterrou a opção do tratamento (apoiando, por exemplo, a patronal nas demissões e perda da vaga escolar de quem não aceitasse as inoculações compulsórias).
Hoje, a censura continua a todo vapor.
Assim como seguem também as mortes desnecessárias que ocorreram/ocorrem (seja pela falta do medicamento, seja por efeitos colaterais das inoculações experimentais; a este respeito cabe mencionar o site norte-americano Vaers, que contabiliza as dezenas de milhares de mortes pelas picadas experimentais e doenças por elas produzidas; assim como cabe tentar contornar a censura e checar vídeos informativos como aqui e aqui; além do já citado acima e, por exemplo, o depoimento do senador Gerard Rennick, aqui). Sempre por fora das redes de informação mainstream.
Então o mal venceu? Os grandes fundos financeiros/Big Pharma impuseram sua agenda antioperária? Sim, não é possível negar.
A Big Pharma venceu, algo que seria previsível, considerando o mundo como ele é, no qual o grande capital controla informações, censura todo o tempo qualquer voz dissidente, constrói a grande narrativa e liquida, através do poder de Estado (privatizado), reputações e carreira de quem se coloque no seu caminho, quem ouse sair denunciando o grande crime.
O grande capital imperialista venceu em toda linha, em um mundo politicamente controlado por ele. Exceções, como o presidente Magufuli, na África, que resistiu à OMS e ao Bill Gates, ocorreram e foram liquidadas.
O que sim surpreendeu e chocou foi assistir ao de certa forma inesperado e sinistro show da esquerda pandêmica.
Essa esquerda, que sempre falou contra o capitalismo, contra a opressão, em defesa do corpo (contra o Estado), capitulou em toda linha à narrativa imperialista da OMS e ao autoritarismo mercenário da OMS. “Todos somos Tedros, todos somos OMS”, pode-se dizer da esquerda organizada mundo afora.
A coisa mais ridícula e a que menos se esperaria da esquerda, mas que aconteceu todo o tempo foi considerar Tedros (o chefe da agência imperialista OMS) como se fosse um cargo técnico, uma figura técnica. Tudo que ele não é, não pode ser, e a esquerda poderia enxergar isso, ver também o papel do vacinólatra e “pilantropo” Bill Gates (maior cotista da OMS) caso a esquerda tivesse preservado sua visão de classe.
Ao agir assim, essa esquerda, toda ela, todo grupo esquerdista com alguma influência, mostrou que opera como força do sistema capitalista e não da classe trabalhadora e foi totalmente funcional para a manipulação pandêmica. Ou seja, ficou claro que a esquerda não age como esquerda. Limita-se a operar como uma força política institucional, reformista, ao menos na sua prática.
Ela virou outra coisa ao agir por fora e contra aquilo que deveria definir a esquerda, a defesa da classe trabalhadora contra os interesses do grande capital, da Big Pharma. Virou esquerda da Big Pharma, esquerda-Pfizer. Como se o grande capital agisse em função do bem comum.
Uma vergonha para um movimento que se define anticapitalista, e no marco de uma pandemia na qual quem lucrou foi o grande capital, enquanto o pequeno comércio era liquidado pela política sanitária dos lockdowns e a infância pagava um preço altíssimo pelo lockdown escolar; e agora pela inoculação compulsória de injeções experimentais.
Todo o tempo da pandemia e do pós-pandemia, a esquerda organizada, de todos os quadrantes do mundo, de todos os matizes, inclusive, claro, a tupiniquim, agiu, agressivamente, como força auxiliar da OMS, como puxadinho da Pfizer, por assim dizer. O MST soltou vídeos para os sem-terra esbravejando contra a ivermectina, “remédio de cavalo” (como sempre, sem qualquer argumento científico e cancelando qualquer debate) e, hoje, é pouco mais que uma agência de imposição de inoculações contra os pobres do campo. E o mais triste: segundo vários cientistas, a ivermectina funciona.
Negacionistas terapêuticos que nada estudam com independência e, em vez disso, se limitam a prestar continência à OMS.
E foi assim que, de uma forma geral, a esquerda prestou grandes serviços ao imperialismo.
Ziau, janeiro 2023
NOTAS:
IVERMECTINA. Redação Médicos Pela Vida (MPV). COVID-19: estudo ´padrão ouro´ comprova eficácia da ivermectina. Disponível em: https://medicospelavidacovid19.com.br/noticias/covid-19-estudo-padrao-ouro-comprova-eficacia-da-ivermectina/ Reflexão ao final do artigo dos MPV: São agora 17 estudos. Vão falar que esse, que apenas confirma os anteriores, não comprova nada e vão fingir demência sobre o conjunto de evidências de todos os outros? Só há um único recurso para vocês, mas só se forem falar apenas desse estudo, da Bulgária. Ele ainda não é revisado por pares. Mas entre os 16 anteriores, a imensa maioria é. Este só confirmou. Vão se agarrar nisso como uma bóia de salvação? Se forem para esse lado, afirmando que falta revisão por pares para dizer que não comprova (resultados assim nunca mudam), vão jogar nas manchetes como “eficaz” após a revisão ou já foram longe demais, passando do ponto de não retorno? Quantos estudos unânimes precisam mais para falarem um “Desculpem. Erramos. Funciona sim e sempre funcionou”? Uns trinta? Cinquenta? Cem? Vão mandar gente para o cemitério por teimosia até quando? Se este fosse o primeiro, até nós, do MPV – Médicos Pela Vida, aguardaríamos a revisão. Mas como confirmou o que a gente já sabe, não é necessário. Leia mais: Ivermectina em Itajaí e também COVID-19: Jornal da USP mente e distorce a ciência para atacar a ivermectina. Leia a análise completa
AFSAR et al., SSRN (Preprint) Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting Small 95 patient study in Pakistan adding ivermectin to standard of care (HCQ+AZ) for outpatients with mild/moderate suspected COVID-19, showing faster resolution of fever with ivermectin. https://c19hcq.com/afsar.html
AHMED et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191 (Peer Reviewed) A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness” - There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings”.
ALAM et al., Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 (Peer Reviewed) A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline “All patients tested negative and their symptoms improved within 72 hours. There were no noticeable side effects. Conclusion: Combination of Ivermectin and doxycycline was found to be very effective in viral clearance in mild and moderately sick COVID-19 patients. Medical societies and institutions should undertake larger multi center studies to validate and recommend this combination therapy to include in national guidelines”. Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported. https://www.researchgate.net/publication/343305357_A_Case_Series_of_100_COVID-19_Positive_Patients_Treated_with_Combination_of_Ivermectin_and_Doxycycline
ALONSO et al., (Preprint) https://c19ivermectin.com/ Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before,
ANGELL M. Is academic medicine for sale? (editorial) N Engl J Med 2000;342(20):1516-8. (PubMed)
ARÉVALO et al., bioRxiv, doi:10.1101/2020.11.02.363242 (Preprint) animal study - Ivermectin reduces coronavirus infection in vivo: a mouse experimental model https://pesquisa.bvsalud.org/portal/resource/pt/ppbiorxiv-363242
BARROWS, N. J., Campos, R. K., et al. (2016). A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell host & microbe, 20(2), 259–270. https://doi.org/10.1016/j.chom.2016.07.004
BEHERA et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint) cases, ? Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: a matched case-control study https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1 Retrospective prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin. HCQ OR 0.56, p = 0.29 Ivermectin O.. - “Conclusion - Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month. Further research is required before its large scale use”.
BERNIGAUD et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231 (Peer Reviewed) Ivermectin benefit: from scabies to COVID-19, an example of serendipity https://c19ivermectin.com/bernigaud.html
Big Pharma. “Big Pharma is America’s New Mafia.” (February 2015). The Daily Beast. Accessed July 26, 2016.
Big Pharma. “Watch John Oliver Skewer the Cozy Relationship Between Doctors and Pharmaceutical Companies.” (February 2015). Business Insider. Accessed July 26, 2016.
Big Pharma. HORWITZ, Sari Horwitz, “Drug industry accused of gouging public,” New York Times, July 16, 1985, p. E1.
Big Pharma. “FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm.” (March 2016). Federal Trade Commission. Accessed July 28, 2017.
Big Pharma. “Medical Money: See What Drug and Device Makers Paid Doctors.” (October 2014). Wall Street Journal. Accessed July 26, 2016.
Big Pharma. “Big Pharma’s Big Fines.” (February 2014). ProPublica. Accessed July 27, 2016.
Big Pharma. “Biopharmaceuticals in Perspective,” Summer 2019, p. 2, at https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/PhRMA_2019_ChartPack_Final.pdf
Big Pharma. “Demonizing “Big Pharma”.” (April 2010). Science-Based Medicine. Accessed July 26, 2016.
Big Pharma. “Do Drug Companies Make Drugs, or Money?” (June 2014). The New York Times. Accessed July 26, 2016,
Big Pharma. “How Big Pharma Gave America Its Heroin Problem.” (November 2015). Pacific Standard. Accessed July 27, 2016.
Big Pharma. “How to Win Doctors and Influence Prescriptions.” (October 2010). NPR. Accessed July 26, 2016.
Big Pharma. “My Love-Hate Relationship With Drug Reps.” (November 2010). Physicians Practice. Accessed July 27, 2016.
Big Pharma. “Sick of Pharmaceutical Ads? Here’s Why They Won’t Go Away.” (October 2011). Io9. Accessed July 25, 2016.
Big Pharma. CNBC, 6/27/18
Big Pharma. How the American Opiate Epidemic Was Started by One Pharmaceutical Company.” (March 2015). The Week. Accessed July 27, 2016.
Big Pharma. https://attac.es/la-avaricia-de-los-gigantes-farmaceuticos/
Big Pharma. https://deserthopetreatment.com/addiction-guide/drug-industry-trends/
Big Pharma. https://deserthopetreatment.com/addiction-guide/drug-industry-trends/
Big Pharma. https://edition.cnn.com/2019/09/12/perspectives/drug-patents-abuse/index.html “Large pharmaceutical companies have continually engaged in the strategic accumulation of patents to restrict patient access to more affordable drugs by delaying the entry of generic options into the market. While some of the additional patents represent true incremental innovation, many are deployed strategically to preserve a company's monopoly rights on the original discovery. All in all, the tactics used are not new or useful, they are simply a way for Big Pharma to maintain their drug monopolies and continue charging American consumers more for drugs than they could if they had competition in the market. By gaming the patent system to secure monopolies on their products, pharmaceutical companies are removing the motivation to innovate because they are simply creating new patents that are similar in scope to previously obtained ones, thus creating a captured market. This lack of competition has resulted in price increases averaging 68% since 2012 for the top selling drugs in the United States”.
Big Pharma. https://finance.yahoo.com/news/10-biggest-pharmaceutical-companies-world-184321012.html
Big Pharma. https://jacobinmag.com/2020/02/coronavirus-outbreak-free-market-pharmaceutical-industry
Big Pharma. https://jacobinmag.com/2020/03/coronavirus-profit-pharmaceutical-industry-antibiotics-superbugs
Big Pharma. https://prospect.org/coronavirus/big-pharmas-game-of-control-covid-drug-treatment/
Big Pharma. https://prospect.org/coronavirus/big-pharmas-game-of-control-covid-drug-treatment/
Big Pharma. https://www.csrxp.org/the-crisis/
Big Pharma. https://www.csrxp.org/the-truth-about-big-pharmas-patent-abuse/
Big Pharma. https://www.ineteconomics.org/perspectives/blog/financialization-us-pharma-industry
Big Pharma. https://www.nakedcapitalism.com/2019/12/financialization-of-the-u-s-pharmaceutical-industry.html
Big Pharma. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1534100/
Big Pharma. https://www.sciencedirect.com/science/article/abs/pii/S0277953620303154
Big Pharma. https://www.statnews.com/2019/07/16/pharma-still-winning/
Big Pharma. https://www.trtworld.com/magazine/who-owns-the-world-s-largest-pharmaceutical-companies-42983
Big Pharma. https://www.trtworld.com/magazine/who-owns-the-world-s-largest-pharmaceutical-companies-42983
Big Pharma. Patent nonsense: Evidence tells of an industry out of social control. Em:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1534100/
Big Pharma. The New York Times, 1/6/18 & I-MAK, 9/18/18
BODENHEIMER T. Uneasy alliance — clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342(20):1539-44. (PubMed)
CADEGIANI et al., medRxiv, doi:10.1101/2020.10.31.20223883 (Preprint) death, ? Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1 Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, ev.. ” Early pharmacological approaches including azithromycin in combination with any of the options between nitazoxanide, ivermectin or optionally hydroxychloroquine should be considered for those diagnosed with COVID-19 presenting less than seven days of symptoms. Of the three drugs, we opted for nitazoxanide, due to more extensive demonstration of in vitro and in vivo antiviral activity, proven efficacy against other viruses in humans, and steadier safety profile”.
CHANGJIELv et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Research, Volume 159, November 2018, Pages 55-2. https://doi.org/10.1016/j.antiviral.2018.09.010
CALY et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, Vol. 178, June 2020, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
CHAMIE, J. (News) The effect of using ivermectin to control COVID-19 in Chiapas https://c19ivermectin.com/chamie.html After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has seen a dramatic divergence from other states with much lower mortality (1, 2).
CHANG et al., ResearchGate (Preprint) Post-acute or prolonged COVID-19: ivermectin treatment for patients with persistent symptoms or post-acute symptoms Report on 33 patients with persistent or post-acute symptoms treated with ivermectin, showing a high rate of clinical improvement. “CONCLUSION: The result of the present study demonstrates that clinical improvement is observed in high percentage of patients with Persistent or Post-Acute Symptoms of COVID-19 who are treated with Ivermectin. Given the high number of patients with Persistent Symptoms and a favorable clinical response seen after receiving this specific treatment, we recommend that additional clinical studies be carried out on the use of Ivermectin and other drugs to reduce and eliminate the viral load in these cases”. https://www.researchgate.net/publication/344318845_POST ACUTE_OR_PROLONGED_COVID-19_IVERMECTIN_TREATMENT_FOR_PATIENTS_WITH_PERSISTENT_SYMPTOMS_OR_POST-ACUTE
CHOWDHURY et al., Research Square, doi:10.21203/rs.3.rs-38896/v1 (Preprint) A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients - “Conclusion The Ivermectin-Doxycycline combination showed a trend toward superiority to the Hydroxychloroquine-Azithromycin combination therapy in the case of patients with mild to moderate COVID19 disease, though the difference in time to becoming symptom-free and the difference in time to negative PCR was not statistically significant”. https://www.researchsquare.com/article/rs-38896/v1
COVID-19 - Inclusión de la ivermectina en la primera línea de acción terapéutica para
COVID-19. Se reporta una muy significativa disminución de la Tasa de Letalidad con su uso. http://dx.doi.org/10.13140/RG.2.2.34689.48482/4
CRUMP, A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot. 2017;70:495–505. https://dx.doi.org/10.1038 /ja.2017.11
CRUMP, A., & Ōmura, S. (2011). Ivermectin, ’wonder drug’ from Japan: the human use perspective. Proceedings of the Japan Academy. Series B, Physical and biological sciences, 87(2), 13–28. https://doi.org/10.2183/pjab.87.13
DEEP STATE. https://en.wikipedia.org/wiki/Deep_state_in_the_United_States
DEEP STATE. https://theprint.in/world/deep-state-fda-is-taking-a-beating-as-review-of-covid-vaccine-approaches/491554/
ELGAZZAR et al., Research Square, doi:10.21203/rs.3.rs-100956/v2 (Preprint) Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic https://www.researchsquare.com/article/rs-100956/v2 ” Conclusion: Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only. Early use of Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving cytokines storm”.
ELGAZZAR, A., Hany, B., et al., Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, 13 November 2020, Research Square preprint, https://doi.org/10.21203/rs.3.rs-100956/v1
FRANCÉS-MONERRIS et al., ChemRxiv, doi:10.26434/chemrxiv.12782258.v1 (Preprint) (Theory) Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent https://chemrxiv.org/articles/preprint/Has_Ivermectin_Virus-Directed_Effects_against_SARS-CoV-2_Rationalizing_the_Action_of_a_Potential_Multitarget_Antiviral_Agent/12782258/1 “Hence, the wide spectrum of actions involving i) the interference with cell infection, ii) the inhibition of viral replication, and iii) elusion of the host immune system, could point to an unprecedented synergy between host- and virus-directed effects explaining the high anti-SARS-CoV-2 activity observed for this compound”.
GEARY, T. G. (2005). Ivermectin 20 years on: maturation of a wonder drug. Trends in parasitology, 21(11), 530–532. https://doi.org/10.1016/j.pt.2005.08.014
GORIAL et al., medRxiv, doi:10.1101/2020.07.07.20145979 (Preprint) death, Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) - “ConclusionsAdd-on use of IVM to HCQ and AZT had better effectiveness, shorter hospital stay, and relatively safe compared with controls. however, a larger prospective study with longer follow up may be needed to validate these results”. https://pesquisa.bvsalud.org/portal/resource/pt/ppmedrxiv-20145979
GUZZO, CA, Furtek CI, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002 Oct;42(10):1122-33. doi: 10.1177/009127002401382731. PMID: 12362927.
HARRIS G. A drug giant thinks it can grow still bigger. New York Times 2003 Jun 19; Sect C:1(col 2).
HASHIM et al., medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint) death, ? Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1 ” Conclusions Ivermectin with doxycycline reduced the time to recovery and the percentage of patients who progress to more advanced stage of disease; in addition, Ivermectin with doxycycline reduced mortality rate in severe patients from 22.72% to 0%; however, 18.2% of critically ill patients died with Ivermectin and doxycycline therapy. Taken together, the earlier administered Ivermectin with doxycycline, the higher rate of successful therapy
HEIDARY, Fatemeh; Gharebaghi, Reza (2020-09). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics, 73 (9): 593-602. http://www.nature.com/articles/s41429-020-0336-z
IVERMECTINA . "A FDA não aprovou a ivermectina para uso no tratamento ou prevenção de COVID-19 em humanos", destaca a nota da agência federal dos EUA. De acordo com os critérios da FDA, a droga é aprovada "em doses muito específicas para alguns vermes parasitas, e existem formulações tópicas (na pele) para piolhos e doenças da pele como a rosácea. A ivermectina não é um antiviral (um medicamento para o tratamento de vírus)". “Pelo mundo, a Agência Nacional de Vigilância Sanitária (Anvisa) também tem posição similar para a não recomendação da ivermectina contra a COVID-19 e defende que "as indicações aprovadas para a ivermectina são aquelas constantes da bula do medicamento". Além disso, a Merck (MSD), que fabrica comprimidos de ivermectina, se posicionou de forma contrária ao uso fora da bula, ressaltando a inexistência de evidências científicas para o seu uso contra o coronavírus. https://canaltech.com.br/saude/agencia-federal-dos-eua-alerta-para-riscos-do-uso-de-ivermectina-contra-covid-19-180381/ em 11-3-2021
IVERMECTINA . ND Notícias. Médico do Paraná. Covid-19: Especialista defende uso de medicamentos para tratamento precoce - 5 de mar. de 2021 – Programa ND Notícias -
IVERMECTINA. "Evaluación del efecto antiviral del fármaco ivermectina contra SARS-CoV-2” https://www.argentina.gob.ar/noticias/un-estudio-demuestra-la-respuesta-antiviral-de-la-ivermectina-en-pacientes-con-covid-19 Instituto de Investigaciones de Enfermedades Tropicales de la Sede regional Orán de la Universidad Nacional de Salta (UNSa), Laboratorio de Farmacología del Centro de Investigación Veterinaria de Tandil (CIVETAN), Universidad Nacional de Quilmes; del Hospital Juan P. Garrahan, y del Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), e integrantes del Laboratorio ELEA-Phoenix,
IVERMECTINA. AAS. Chang et al., ResearchGate, doi:10.13140/RG.2.2.34561.48483/2 (Preprint) COVID-19: Post-exposure prophylaxis with ivermectin in contacts. At Homes, Places of Work, Nursing Homes, Prisons, and Others - “The inclusion of Acetylsalicylic Acid (ASA) or Aspirin in the PEP Schedule should be considered for men over 55 years of age and in persons with Increased Risk of developing
severe illness. Recommended dose is 1 tablet of 100 mg after lunch for 6 to 10 days.
Contacts should remain under observation in case they begin to show characteristic symptoms of COVID-19, in which case they should move to therapeutic doses of Ivermectin”.https://www.researchgate.net/publication/344781515_COVID-19_POST-EXPOSURE_PROPHYLAXIS_WITH_IVERMECTIN_IN_CONTACTS_At_Homes_Places_of_Work_Nursing_Homes_Prisons_and_Others
IVERMECTINA. Bangladesh: ivermectin shows promise in treating vírus - https://www.aa.com.tr/en/asia-pacific/bangladesh-ivermectin-shows-promise-in-treating-virus/2068885
IVERMECTINA. Belgian Virologist Proposes a Plan to Eradicate COVID-19 in 6 Weeks Using Ivermectin - Fev 2021 https://trialsitenews.com/belgian-virologist-proposes-a-plan-to-eradicate-covid-19-in-6-weeks-using-ivermectin/ “Referencing the meta-analysis from Dr. Tess Lawrie in the UK, the Belgian virologist shares that based on 15 randomized controlled trials and observational controlled trials, the ivermectin treatment reduces deaths by an average of 83% (95% Cl 65%-92%). He shares that based on the Dr. Lawrie meta-analysis, the drug also reduces the risk of deterioration by 53% (95% Cl 23%-71). Furthermore, Wathelet cites Lawrie that the drug used as prophylaxis given to health care workers or relatives can reduce the risk of infection by 88% (95% Cl 82%-92%). He aligns with America-based Front Line COVID-19 Critical Care Alliance (FLCCC) “.
IVERMECTINA. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study https://www.alliedacademies.org/abstract/effects-of-ivermectinazithromycincholecalciferol-combined-therapy-on-covid19-infected-patients-a-proof-of-concept-study-14435.html
Small study with 28 patients treated with ivermectin + AZ + cholecalciferol and 7 control patients. All treated patients were PCR- at day 10 while all control patients remained PCR+. “This study found that the combination treatment might mitigate disease progression without significant adverse effects. Further studies are needed in order to extrapolate these findings to moderate and severe COVID-19”.
IVERMECTINA. http://conselho.saude.gov.br/ultimas-noticias-cns/1570-cns-pede-que-ministerio-da-saude-retire-publicacoes-sobre-tratamento-precoce-para-covid-19 Em janeiro de 2021 o Conselho Nacional de Saúde pede que Ministério da Saúde elimine publicações sobre tratamento precoce da COV-19. (http://conselho.saude.gov.br/ultimas-noticias-cns/1570-cns-pede-que-ministerio-da-saude-retire-publicacoes-sobre-tratamento-precoce-para-covid-19). “O presidente do CNS, Fernando Pigatto, destaca que desde o início da pandemia o Conselho tem se posicionado contrário à indicação de qualquer medicamento para tratamento da Covid-19 sem eficácia comprovada. “O que foi reafirmado pela Anvisa, em coletiva no último domingo (17/1), durante o anúncio das vacinas. Portanto, estamos orientando por ofício que sejam revogadas toda e qualquer publicação do MS que orientem o tratamento precoce”, destaca Pigatto”.
IVERMECTINA. http://pharmabaires.com/1767-salta-y-corrientes-adoptan-ivermectina-en-sus-protocolos-covid.html
IVERMECTINA. http://pharmabaires.com/1767-salta-y-corrientes-adoptan-ivermectina-en-sus-protocolos-covid.html
IVERMECTINA. http://www.cofen.gov.br/anvisa-esclarece-que-ivermectina-nao-e-indicada-contra-covid-19_81155.html
IVERMECTINA. https://canaltech.com.br/saude/agencia-federal-dos-eua-alerta-para-riscos-do-uso-de-ivermectina-contra-covid-19-180381/ em 11-3-2021
IVERMECTINA. https://megalabs.global/peru-comienza-la-produccion-masiva-de-ivermectina/
IVERMECTINA. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-896543 100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment. “Our study supports the benefits of utilization of combination of Doxycycline and Ivermectin in mild to moderate COVID-19 infection in terms of early recovery based on the time for symptom resolution and the mean duration of hospital stay”
IVERMECTINA. https://www.cardioinfantil.org/recados-unidad-sintesis-transferencia/ivermectina-y-covid-19/
IVERMECTINA. https://www.las2orillas.co/ivermectina-la-formula-contra-el-covid-que-en-cali-esta-funcionado/
IVERMECTINA. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? - Review of ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2. Cell culture experiments show robust antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, V.. https://pubmed.ncbi.nlm.nih.gov/32942671/ - “This mini-review discusses the case for ivermectin as a host-directed broad-spectrum antiviral agent for a range of viruses, including SARS-CoV-2”. -
IVERMECTINA. Ivermectin medicine to be used for Covid-19 treatment in Uttar Pradesh
https://www.knocksense.com/lucknow/ivermectin-medicine-to-be-used-for-covid-19-treatment-in-uttar-pradesh
IVERMECTINA. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled Trial https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04813-1
IVERMECTINA. Un estudio demuestra la respuesta antiviral de la ivermectina en pacientes con COVID-19 - https://www.argentina.gob.ar/noticias/un-estudio-demuestra-la-respuesta-antiviral-de-la-ivermectina-en-pacientes-con-covid-19
IVERMECTINA.https://www.reddit.com/r/COVID19/comments/hk75iz/ivermectin_for_covid19_treatment_clinical/
IVERMECTINA.https://www.reddit.com/r/ivermectin/comments/l7iwld/ivermectin_to_save_belgium_belgium_20201222/
JANS, D. A., & Wagstaff, K. M. (2020). The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?. Biochemical and biophysical research communications, S0006-291X(20)31959-8. Advance online publication. https://doi.org/10.1016/j.bbrc.2020.10.042
KHAN et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007 (Letter) Ivermectin treatment may improve the prognosis of patients with COVID-19 - https://www.archbronconeumol.org/es-ivermectin-treatment-may-improve-prognosis-articulo-S030028962030288X - “Therefore, given the urgent need to manage the COVID-19 patients with a safe, cheap and widely available drug, the present findings suggest that ivermectin can be considered as a first-line treatment for containing SARS-CoV-2 to prevent severe irreversible respiratory complications and community transmission. A multicenter, double-blind, drug-controlled study will strengthen our findings”.
LAZONICK. William Lazonick and Öner Tulum, “US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model,” Research Policy, 40, 9, 2011: 1170-1187
LEHRER et al., In Vivo, 34:5, 3023-3026, doi:10.21873/invivo.12134 (Theory) Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 https://www.x-mol.com/paper/1302073874220027904?recommendPaper=5812856 In silico analysis showing ivermectin docking which may interfere with the attachment of the spike to the human cell membrane.
LEON CALY, Julian D Druce et al - The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro – “We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans”.
“ - https://www.sciencedirect.com/science/article/pii/S0166354220302011
MAHMUD et al., Clinical Trial Results, NCT04523831 (Preprint) Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 180 control patients.
MOMEKOV et al., Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Journal Biotechnology & Biotechnological Equipment, 05 Jun 2020.
NGUYEN et al. Therapeutic use of ivermectin against nuclear viruses in all animals: Nguyen et al., Ivermectin blocks the nuclear location signal of parvoviruses, Aquaculture, Vol. 420/1, 15/01/14, Pg. 288-294. https://doi.org/10.1016/j.aquaculture.2013.11.022
NIAEE et al., Research Square, doi:10.21203/rs.3.rs-109670/v1 (Preprint) Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases. https://www.researchsquare.com/article/rs-109670/v1 “ Ivermectin as an adjunct reduced the rate of mortality, low O2 duration, and duration of hospitalization in adult COVID 19 patients. The improvement of other clinical parameters showed that the ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19”.
(88 ) Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed) Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-
PATRI et al., Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, Journal of the American Academy of Dermatology, Volume 82, ISSUE 6, e221, June 01, 2020. https://doi.org/10.1016/j.jaad.2020.04.017
PEÑA-SILVA, R. et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19, 17 July 2020 https://doi.org/10.1111/bcp.14476
PETERSON M. Madison Ave. has growing role in the business of drug research. New York Times 2002 Nov 22
RAHMAN et al., J. Bangladesh Coll. Phys. Surg. 38, 5-9, doi:10.3329/jbcps.v38i0 (Peer Reviewed) Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients - “Conclusion: It appears Ivermectin and Doxycycline is safeand effective combination drug therapy in COVID- 19infected patients but need further extensive study to find out the scope of application on other groups of patients”. https://www.banglajol.info/index.php/JBCPS/article/view/47514
RAJTER et al., Chest, doi:10.1016/j.chest.2020.10.009 (Peer Reviewed) death, ? Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study) https://pubmed.ncbi.nlm.nih.gov/33065103/ ” Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement”. Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 (0.22-0.99), p=0.045.
RAJTER et al., Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients in COVID19, medRxiv. 2020 https://doi.org/10.1101/2020.06.06.20124461
REZAI et al., IRCT20111224008507N3 (Preprint) Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020 RCT in Iran showing shorter time to clinical recovery with Ivermectin. Results are from: (1) https://c19study.com/rezai.html
RIZZO, E., Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn-Schmiedeberg’s Arch Pharmacol 393, 1153–1156 (2020). https://doi.org/10.1007/s00210-020-01902-5
SHAPIRO D. Drug companies get too close for med school's comfort. New York Times 2004 Jan 20.
SMIT, M, Ochomo E, et al., Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial, The Lancet Infectious Diseases, March 27, 2018, ISSN: 1473-3099, Vol: 18, Issue: 6, Page: 615-626 DOI: https://doi.org/10.1016/S1473-3099(18)30163-4
TAY, M. Y., Fraser, J. E., et al. (2013). Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral research, 99(3), 301–306. https://doi.org/10.1016/j.antiviral.2013.06.002
VACINAS. “Pfizer Pays $2.3 Billion to Settle Marketing Case.” (September 2009). The New York Times. Accessed July 25, 2016.
VACINAS. https://www.nytimes.com/2020/10/20/health/covid-vaccines-fda-trump.html
VARGHESE, F. S., Kaukinen, P., et al. (2016). Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral research, 126, 117–124. https://doi.org/10.1016/j.antiviral.2015.12.012
VEBLEN , T. 1908b. "On the Nature of Capital: Investment, Intangible Assets, and the Pecuniary Magnate". The Quarterly Journal of Economics 23:104-136.
WAGSTAFF, et al.Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443 (3) (2012), pp. 851-856 Citado en: https://doi.org/10.1016/j.antiviral.2020.104787
WAGSTAFF, K.M. et al.An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import, J. Biomol. Screen, 16 (2) (2011), pp. 192-200
YANG et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Research, Volume 177, May 2020, 104760. https://doi.org/10.1016/j.antiviral.2020.104760
YANG, S., Atkinson, S. C., et al. (2020). The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral research, 177, 104760. https://doi.org/10.1016/j.antiviral.2020.104760
- - -